Three working groups support workpackage 6

WORKPACKAGE 6

Building and validation of a DCIS risk stratification model

In WP6 we will build a DCIS risk stratification model and develop a clinical assay based on molecular characteristics. We will use the data generated in WP1 (clinico-pathological data), WP2 (mutational data), WP3 (Immune infiltrate, heterogeneity), and WP4 (imaging) in a half as test and half as validation set.

The main lines of research are:

1.	To assess the relative risk of a future event after a primary diagnosis of DCIS only. To this end we will both set up logistic regression models for the risk of a future in situ diagnosis as well as a future invasive event in the training dataset.
2.	We will use these data to build a robust DCIS risk prediction model on the training data set. When a model with a good fit has been built it will be tested on the test dataset.
3.	With the molecular markers identified, we will develop an easy to use, molecular-based assay which can be used in the clinic. To reach this aim, we will define the most discriminating molecular markers and bring them together in one focused assay.

Workpackage 6 is responsible for the respective project objectives to deliver a validated DCIS risk stratification model and to deliver a proof of concept diagnostic assay for prospective validation

Milestones

6.1	Collection and curation of all clinical and pathology data from DCIS retrospective cohorts
6.2	First analysis on RR/OR of combined clinic-pathological data
6.3	First model incorporating clinical, molecular and imaging data on training dataset
6.4	Validation of the model
6.5	Diagnostic assay developed

Three working groups support workpackage 6